

Methotrexate in Rheumatoid Arthritis : A 2 Year Experience at a University Hospital in Pakistan

Pages with reference to book, From 3 To 6

Azra A. Ali, M. Azmat Hussain (Departments of Medicine, The Aga Khan University, Karachi.)
M. Perwaiz Iqbal, N. Mehboobali (Departments of Biochemistry, The Aga Khan University, Karachi.)
Javed A. Beg (Departments of Health Sciences, The Aga Khan University, Karachi.)

Abstract

In this study we report our two years experience of methotrexate (MTX) in the management of rheumatoid arthritis (RA) at the Aga Khan University Hospital, Karachi. We studied the clinical course of 124 RA patients. The mean age was 44 ± 11 years (range 19-72) and mean duration of RA was 5 ± 4 years (range 0.3 -25). Female to male ratio was 10:2.4(100F:24M). All of them were diagnosed according to the criteria set by American Rheumatism Association. The mean value of ESR was 60 ± 30 (Range 3-128). Fifty one percent had severe disease (>10 joints involved and evidence of erosions and deformities). Twenty-one patients had extra-articular manifestations. None of them had received MTX previously. Their kidney and liver functions were assessed to be normal. Patients were divided into two groups. One group (n=92) received MTX (7.5- 10 mg/week) as initial treatment, while the other group (n=32) was given other disease modifying anti-rheumatic drugs (penicillamine, salazopyrin, gold, or chioroquine) followed by MTX. Assessment of the treatment outcome and development of any adverse reactions was carried out at 3-month interval over an average period of 1 year. Assessment of the treatment outcome in the group which received MTX as initial drug revealed the response to be excellent in 13%, good in 70%, fair in 11% and variable in 4%. In the group which received MTX as second-line of therapy, 59% of the patients had the response from good to excellent, while 25% of the patients exhibited poor to fair response. Regarding side-effects of MTX treatment, 57% exhibited none, while 35% had nausea and vomiting. Alopecia was the next common toxicity in these patients. Two individuals had abnormal liver function tests (value twice more than normal), while one developed lung fibrosis. MTX despite its adverse effects in some of the patients is still an effective, well tolerated and inexpensive disease modifying drug in RA (JPMA 48:3, 1998).

Introduction

Rheumatoid arthritis (RA) is increasingly recognized in Pakistan. In a study carried out few years ago, its prevalence in Karachi alone has been reported to be 0.15%¹. Because of a heavy burden of infectious diseases, hypertension, coronary artery disease and diabetes, there are relatively few rheumatology clinics in the country and therefore, there is hardly any information available about the treatment outcome of this disease. Methotrexate (MTX), over the past few years, has emerged as the most frequently used disease modifying antirheumatic drug (DMARD) in the U.S.A. for the treatment of RA². Because of its excellent efficacy score and relatively low serious toxicity score^{3,4}, it is being recognized as one of the leading therapies in the aggressive intervention of RA. The remarkable aspect of this therapy was the use of low dosages (7.5 mg - 15 mg/week) resulting in significant improvement in most variables of disease activity compared to placebo controls⁵⁻⁸. However, its use in the management of RA has been quite limited in Pakistan. The objective of this study was to investigate the effectiveness and tolerability of MTX in our RA population.

Patients and Methods

A retrospective analysis was performed on 124 RA patients who had been receiving MTX at the Rheumatology Clinic of The Aga Khan University, Karachi, during the years 1994-95. This follow-up of 2 years was performed on all the patients regardless of whether they used MTX as initial drug or as second-line of treatment. They were divided into two groups, one group (n=92) received MTX (7.5-10 mg/week) as initial treatment while the other group (n=32) received other disease modifying drugs (D-penicillamine, n=19; salazopyrin, n=9; gold, n=2; chloroquine, n=2) followed by MTX, because the response with the initial drug was not satisfactory. Disease severity was scored arbitrarily on a 3-point scale (mild, moderate and severe) on the basis of duration of morning stiffness, Ritchie Index, number of active joints, number of deformities and number of extra-articular features. Women with child bearing potential were advised to avoid pregnancy. Every patient was examined at an interval of 8-10 weeks for the above mentioned parameters. Complete blood count, erythrocyte sedimentation rate, liver enzymes and serum creatinine were measured every 3-4 months. If the values for liver enzymes and serum creatinine were measured every 3-4 months. If the values for liver enzymes increased to more than twice the upper limit of normal, the drug was withheld and the tests were repeated after 2 weeks. Adverse drug reactions during MTX treatment were recorded and classified as those (i) requiring discontinuation of MTX, (ii) requiring suspension of MTX, (iii) and those requiring no change in treatment. Assessment of clinical outcome of the treatment on every patient was carried out at every 3-4 months interval with the following arbitrary designations modified from those proposed by Wemblatt et al⁵.

Excellent: Complete therapeutic remission, defined by the preliminary criteria of American Rheumatism Association⁹.

Good: Remission of 50% of active joints.

Fair: Good Clinical response with less than 3 active joints.

Variable: Mixed remissions and flare-ups.

Results

The demographic and clinical characteristics of RA patients in this study have been listed in Table I.

Table I. Demographic and clinical characteristics of the RA patients receiving MTX at AKUH.

Variable	Frequency (%)	
Sex	Male	24 (19)
	Female	100 (81)
Habitat	Urban	105 (85)
	Rural	19 (15)
Family History:	Nearest blood relative with RA	3 (2)
	Distant relative with RA	5 (4)
	None	116 (94)
Mean age \pm SD	44 \pm 11 years (range 19-72)	
Mean duration of RA symptoms \pm SD	5 \pm 4 years (range 0.3-25)	
Mean ESR \pm SD	60 \pm 30 (range 3-128)	
Disease activity	Mild (1-2 active joints)	16 (13)
	Moderate (3-10 active joints)	45 (36)
	Severe (More than 10 active joints)	63 (51)
Rheumatoid factor	Positive (+/51: ++/23: +++/32)	106 (86)
	Negative	18 (15)
Number of deformities	Hands or feet	31 (25)
	Both hands and feet	27 (22)
	None	66 (53)

All of them were diagnosed according to the criteria set by American Rheumatism Association. None of them had received MTX previously. Their kidney and liver functions were assessed to be normal. RA patients to receive MTX as initial drug or as second line of treatment were included in this study. Twenty-one out of these 124 RA patients had extra-articular manifestations. Seven of them had single extra-articular manifestation while 14 of them had multiple extra-articular manifestations as listed in Table II.

Table II. Extra-articular manifestations in RA patients.

Manifestations	No. of cases
Nodules	1
Cutaneous vasculitis	3
Eye involvement	2
Neuropathy	1
Nodules + Neuropathy	1
Nodules + Sicca (Eye and Mouth)	1
Eye + Neuropathy	2
Nodules + Cut. vasculitis	2
Sicca (Eye & Mouth)	2
Nodules Sicca (Eye and Mouth)	1
Cut. vasculitis + Lymphadenopathy	1
Cut. vasculitis + Neuropathy	1
Lymphadenopathy + Neuropathy	2
Cut. vasculitis + Sicca (Eye & Mouth)	1
Total	21

Table III. Classification of the disease in terms of severity.

Stage of the Disease	Features
Mild	Involvement of 1-2 joints, no extra-articular manifestation and no deformities.
Moderate	Involvement of 3-10 joints, evidence of erosions, extra-articular manifestations and no deformities of either hands or feet.
Severe	Involvement of more than 10 joints, extra-articular manifestations and deformities of either hands or feet.

Table III shows classification of the disease in terms of severity. Nearly half of our patients (51%) had severe disease (involvement of more than 10 joints, evidence of erosions and deformities in hands or feet), while 36% had moderate disease (involvement of 3-10 joints, evidence of erosions in the radiograph and no deformities), 13% had mild disease (involvement of 1-2 joints and no erosions or deformities). A vast majority of them had been on nonsteroidal anti-inflammatory drugs.




Figure 1. Frequency of prodrome symptoms in RA patients.

Figure I, shows the frequency of prodrome symptoms, with forty-eight percent of the patients reporting no symptoms. Assessment of the treatment outcome was carried out at approximately 3-4 months interval over an average period of 1 year for each patient. It revealed marked clinical improvement in

subjects who received MTX as initial drug for atleast 6 months. Results are shown in Figure 2.




Figure 2. Treatment outcome in RA patients receiving MTX as initial drug (n=92).

Results of treatment outcome in the second group (n=32) who received MTX as second line of therapy, are shown in Table IV.

Table IV. Treatment outcome in RA patients who received MTX as second-line of therapy (n=32).

Initial DMARD	Total # of patients (n)	Treatment outcome									
		Excellent		Good		Fair		Variable		Lost to followup	
		n	%	n	%	n	%	n	%	n	%
Salazopyrin	9	1	11	5	56	-	-	1	11	2	22
Penicillamine	19	4	21	6	32	4	21	2	10	3	16
Chloroquine	2	-	-	1	50	-	-	1	50	-	-
Gold	2	2	100	-	-	-	-	-	-	-	-

Most of the patients (82%) had received salazopyrin or penicillamine as initial DMARD, while 2 were on chloroquine and 2 on gold. However, due to intolerance or poor response, these patients were changed to MTX therapy. Again, in most of them (59%), the response to MTX therapy was good to excellent. There were 4 patients in this group in whom the response was fair, while 4 patients did not respond to therapy and had to be put on another DMARD. Five patients were lost to follow-up.




Figure 3. Major side-effects of MTX treatment in RA patients.

Figure 3 shows the side effects of MTX treatment. Nausea and vomiting were the major adverse reactions in 35% patients. Alopecia was experienced by 31% individuals and there were two cases of abnormal liver enzymes (more than twice the normal maximum limit) and one case of lung fibrosis. Fifty-seven percent of our patients (71 cases) had no major adverse reactions. No haematological toxicity was observed.

Discussion

This open study carried out on our RA population shows the tolerability and effectiveness of low-dose MTX treatment which has emerged to be one of the inexpensive disease modifying therapies in the management of RA. These results pertaining to the short-term efficacy of low-dose MTX in RA compare well with those reported by Weinblatt et al⁵ who had shown excellent response in 24% of the patients. Seventy-three percent of their patients had at least 30% improvement in joint tenderness/pain index. However, that study was a double-blind cross-over trial comparing oral MTX with placebo, while our's is an open study. Similarly, an open study involving 21 patients carried out by Steinsson et al¹⁰ indicated that 52% of their patients responded well to MTX (7.5 mg - 15 mg/week). In another placebo-controlled study by Williams et al⁶ involving 189 patients and an oral dose of MTX 7.5 mg and 15 mg/week over a period of 18 weeks, there was a significant improvement in all disease variables in MTX-group compared to placebo. The above mentioned 3 studies indicate the short term efficacy of MTX treatment and conform well to our results. A number of long term prospective studies have shown

that patients with RA remain on MTX longer than the other slow acting drugs¹¹. According to Weinblatt, 63% of patients continued this therapy for atleast 65 months¹². Buchbinder has reported that 75% of their patients were still on MTX treatment even after 70 months¹³. However, long term use of low dose MIX has not been without adverse reactions¹⁴. A study by McKendry and Dale reported a 75% risk of treatment termination at 60 months¹⁵, while another 3 studies have indicated that risk to be around 50%^{11,16,17}. The discontinuation of treatment due to toxicity has been attributed mainly to the long term use of MIX and total amount of the drug used during that period of time. Since in our study the exposure of our patients to MIX was for a relatively short period (one year average), we did not encounter any serious complications except lung fibrosis in one patient and consistent elevation of liver enzymes in two cases. The patient developing lung fibrosis had a pre-existing chronic lung disease. Although, pulmonary fibrosis is an extreme rarity in MIX therapy, the possibility that MIX treatment may have precipitated, it is a possibility. Hematological toxicity is another reported hazard of low dose MIX therapy¹⁸ yet none of our patients exhibited any symptoms of bone marrow suppression. This could be attributed again to a shorter duration of MIX treatment and a relatively younger age group (mean age 44 years) of subjects. Development of clinically significant liver disease is the most serious side- effect of long term MIX treatment¹⁹. The American College of Rheumatology has recommended guidelines for monitoring liver toxicity²⁰, where if 5 of 9 determinations of liver enzymes within a 12-month period are above the upper limit of laboratory normal, a liver biopsy should be performed to identify potential risk for clinically significant liver disease. Two of our patients developed abnormal values of liver enzymes that persisted for nearly 3 months. They were taken off MIX therapy and were put on different DMARD. Nausea and vomiting were the major symptoms which were managed either by using anti-emetics or in few cases withholding MIX treatment for a short period. Another possible reason for better tolerability of MTX by our RA patients could be the younger age group (mean age 44 years) and normal kidney and liver function. It has been reported that patients who develop MIX toxicity are significantly older compared to those who do not experience such adverse effects²¹. MIX, despite its adverse effects in some patients, remains an effective, well tolerated and inexpensive disease modifying drug in the management of RA. A more recent report by Weinblatt shows its long term effectiveness and superior efficacy to auranofin, azathioprin and cyclosporin A²². It has emerged as a standard therapy for the treatment of active RA. Our two year experience at the Aga Khan University Hospital with this drug proves that by following the standard guidelines for the management of RA²³ MTX therapy could be reasonably safe and effective.

Acknowledgement

We gratefully acknowledge Prof M. Anwar Waqar, Chairman, Department of Biochemistry, The Aga Khan University, Karachi, for reviewing this manuscript.

References

1. Gibson, T. and Hameed, K. The prevalence of rheumatoid arthritis in two urbanized Pakistani populations. Scientific Abstracts. 57th meeting of the American College of Rheumatology, Atlanta, American College of Rheumatology, 1993, p. A-17.
2. Gardner, G. and Furat, D.E. Disease modifying antirheumatic drugs: Potential effects in older patients. *Drugs Aging*, 1995;7:420-37.
3. Felson, D.T, Anderson, J.J. and Meenan, R.F. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis. *Arthritis Rheum.*, 1990,33:1449-61.

4. Felson, D.T., Anderson, J.J. and Meensn, R.F. Use of short-term efficacy/toxicity tradeoffs to select second line drugs in rheumatoid arthritis. *Arthritis Rheum.*, 1992;35:1 117-25.
5. Weinblatt, M.E., Coblyn, J.S., Fox, D.A. et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. *N. Engl. J. Med.*, 1985;312:818-22.
6. Williams, H.J., Wilkens, R.F., Ssmuelson, C.O. et al. Comparison of low dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial, *Arthritis Rheum.*, 1985;28:721-30.
7. Anderson, J.J., West, J.C., O'Dell, J.R. et al. Weekly pulse methotrexate in rheumatoid arthritis: Clinical and immunologic effects in a randomized, double-blind study. *Ann. Intern. Med.*, 1985;103:489-96.
8. Furst, D.E., Koehnke, R., Burmeister, L.F. et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J. Rheumatol.*, 1989;16:313-20.
9. Pinals, R.S., Tvtasi, A.T., Larsen, R.A. et al. Preliminary criteria for clinical remission in rheumatoid arthritis. *Arthritis Rheum.*, 1981;24:1308-15.
10. Steinsson, K., Weinstein, A., Kom, J. et al. Low-dose methotrexate in rheumatoid arthritis. *J. Rheumatol.*, 1982;9:860-6.
11. Conghan, P.G., Quin, D.I., Brooks, P.M. et al. Hazard of low dose methotrexate. *Aust. N.Z. J. Med.*, 1995;25:670-673.
12. Wolfe, R., Hawley, D.J. and Costey, M.A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis. A 14 year prospective evaluation of 1017 consecutive starts. *3. Rheumstol.*, 1990;17:994-1002.
13. Winblatt, M.E. and Maier, A.L. Long term experience with low dose weekly methotrexate in rheumatoid arthritis. *J. Rheumatol.*, 1990;17:33-38.
14. Buehbinder, R., Hall, S., Sambrook, P.N. et al. Methotrexate therapy in rheumatoid arthritis. A life table review of 587 patients treated in community practice. *3. Rheumatol.*, 1993;20:639-44.
15. Sandoval, D.M., Alareon, G.S. and Morgan, F.L. Adverse events in methotrexate-treated rheumatoid arthritis. *Br. J. Rheumatol.*, 1995;34(suppl.2):49-56.
16. McKendry, R.J.R. and Dale, P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. *J. Rheumatol.*, 1993;20:1850-56.
17. Alorcon, G.S., Tracey, L.C. and Blackburn, W.D. Methotrexate in rheumatoid arthritis-Toxic effects as the major factor in limiting long-term treatment. *Arthritis Rheum.*, 1989;32:671-76.
18. Sany, A., Maya, M., Lussiez, V. et al. Treatment of rheumatoid arthritis with methotrexate: A prospective open long-term study of 191 cases. *J. Rheumatol.*, 1991;18:1323-27.
19. Weinstein, A., Marlowe, S., Korn, J. et al. Low-dose methotrexate treatment of rheumatoid arthritis. Long term observations. *Am. J. Med.*, 1985;79:33-37.
20. Kremer, J.M., Alareori, G.S., Lightfoot, R.W. et al. Methotrexate for rheumatoid arthritis. *Arthritis Rheum.*, 1994;37:316-328.
21. Fehlaue, C.S., Carson, C.W., Cannon, G.W. et al. Methotrexate therapy in rheumatoid arthritis. 2 years retrospective follow-up study. *J. Rheumatol.*, 1989;16:307-312.
22. Weinblatt, M.E. Efficacy of methotrexate in rheumatoid arthritis. *Br. J. Rheumatol.*, 1995;34 (suppl. 2):43-48.
23. American College of Rheumatology Adhoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. *Arthritis Rheum.*, 1996;39:713-22.